SUNSHINE BIOPHARMA INC (SBFM) Stock Price & Overview

NASDAQ:SBFM • US8677817004

Current stock price

1.0075 USD
+0.01 (+0.75%)
Last:

The current stock price of SBFM is 1.0075 USD. Today SBFM is up by 0.75%. In the past month the price decreased by -8.41%. In the past year, price decreased by -19.4%.

SBFM Key Statistics

52-Week Range0.953 - 2.43
Current SBFM stock price positioned within its 52-week range.
1-Month Range0.953 - 1.1714
Current SBFM stock price positioned within its 1-month range.
Market Cap
4.947M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-51.88
Dividend Yield
N/A

SBFM Stock Performance

Today
+0.75%
1 Week
-3.13%
1 Month
-8.41%
3 Months
-17.42%
Longer-term
6 Months -51.79%
1 Year -19.40%
2 Years -94.24%
3 Years -99.92%
5 Years N/A
10 Years N/A

SBFM Stock Chart

SUNSHINE BIOPHARMA INC / SBFM Daily stock chart

SBFM Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to SBFM. When comparing the yearly performance of all stocks, SBFM is a bad performer in the overall market: 85.91% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SBFM Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to SBFM. While SBFM seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SBFM Earnings

On April 3, 2026 SBFM reported an EPS of -0.54 and a revenue of 8.58M. The company missed EPS expectations (-96.08% surprise) and missed revenue expectations (-15.91% surprise).

Next Earnings DateMay 13, 2026
Last Earnings DateApr 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.54
Revenue Reported8.577M
EPS Surprise -96.08%
Revenue Surprise -15.91%

SBFM Forecast & Estimates

7 analysts have analysed SBFM and the average price target is 6.12 USD. This implies a price increase of 507.44% is expected in the next year compared to the current price of 1.0075.

For the next year, analysts expect an EPS growth of 98.01% and a revenue growth -0.21% for SBFM


Analysts
Analysts82.86
Price Target6.12 (507.44%)
EPS Next Y98.01%
Revenue Next Year-0.21%

SBFM Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

SBFM Financial Highlights

Over the last trailing twelve months SBFM reported a non-GAAP Earnings per Share(EPS) of -51.88. The EPS increased by 89.45% compared to the year before.


Income Statements
Revenue(TTM)36.31M
Net Income(TTM)-5.98M
Industry RankSector Rank
PM (TTM) N/A
ROA -19.87%
ROE -25.94%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%46%
Sales Q2Q%-10.61%
EPS 1Y (TTM)89.45%
Revenue 1Y (TTM)4.1%

SBFM Ownership

Ownership
Inst Owners5.24%
Shares4.91M
Float4.90M
Ins Owners0%
Short Float %2.86%
Short Ratio3.69

About SBFM

Company Profile

SBFM logo image Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 52 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

Company Info

IPO: 2008-08-15

SUNSHINE BIOPHARMA INC

333 Las Olas Way, Cu4 Suite 433

FORT LAUDERDALE FLORIDA US

Employees: 52

SBFM Company Website

SBFM Investor Relations

Phone: 19543300684

SUNSHINE BIOPHARMA INC / SBFM FAQ

Can you describe the business of SUNSHINE BIOPHARMA INC?

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 52 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.


What is the stock price of SUNSHINE BIOPHARMA INC today?

The current stock price of SBFM is 1.0075 USD. The price increased by 0.75% in the last trading session.


What is the dividend status of SUNSHINE BIOPHARMA INC?

SBFM does not pay a dividend.


How is the ChartMill rating for SUNSHINE BIOPHARMA INC?

SBFM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the analyst forecast for SBFM stock?

7 analysts have analysed SBFM and the average price target is 6.12 USD. This implies a price increase of 507.44% is expected in the next year compared to the current price of 1.0075.


Who owns SUNSHINE BIOPHARMA INC?

You can find the ownership structure of SUNSHINE BIOPHARMA INC (SBFM) on the Ownership tab.


Can you provide the short interest for SBFM stock?

The outstanding short interest for SUNSHINE BIOPHARMA INC (SBFM) is 2.86% of its float.